Actively Recruiting
Phase 1 Study of TX103 CAR-T Cell Therapy for Safety and Effectiveness in Adults With Recurrent or Progressive Grade 4 Glioma
Led by Tcelltech Inc. · Updated on 2026-03-24
52
Participants Needed
4
Research Sites
39 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating the safety, tolerability, and antitumor activity of TX103, an anti-B7-H3 CAR-T cell injection, in adults with recurrent or progressive Grade 4 glioma, including glioblastoma and other high-grade brain tumors. This phase I, open-label study aims to find the maximum tolerated dose and recommend a dose for future studies. The trial is sponsored by Tcelltech Inc. and focuses on patients who have experienced disease progression after standard treatments.
CONDITIONS
Brief Title
Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma.
Research Team
R
Rui Feng, MD
X
Xianzhen Chen, MM
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
